Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in csDMARD-IR moderate to severe rheumatoid arthritis (China)
CTR20170970Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in rheumatoid arthritis (RA), sponsored by AbbVie Inc.. Started Dec 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20170970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170970.